Medical device marketing is business-to-business marketing with a regulator in the room. The buying committee is unusually crowded, since a clinician champions the device, a value analysis committee scrutinises the evidence, supply chain negotiates and a hospital executive signs; the sales cycle is long; and every public claim about what a device does has to sit inside what its clearance or approval supports. That last constraint is what separates a genuine medtech agency from a competent generalist. This guide covers what the engagement actually contains, how regulatory review changes the workflow and the timeline, what moves the retainer, and how to check a firm on evidence you can inspect rather than on the logos in the deck.
Who you are actually marketing to
Map the committee before you brief anyone. The clinical champion cares about outcomes, workflow fit and what colleagues at peer institutions have experienced. The value analysis committee cares about clinical evidence, total cost and whether the device displaces something already contracted. Supply chain and procurement care about price, terms and vendor risk. If you sell direct to patients or to consumers, that is a fourth audience with a different message and a stricter set of advertising constraints. An agency that proposes one message for all of them has not worked in this market. Ask candidates to sketch the committee for your specific device and to say which asset serves which role: the clinical summary, the economic model, the workflow video, the peer reference. That sketch is the fastest way to tell experience from enthusiasm.
How regulatory review shapes the work
In medtech, marketing claims are bounded by the device's regulatory status and by what the cleared or approved indications for use actually say, and the FDA classifies devices by risk with different pathways attached. Practically, this means every piece of public content passes a review by regulatory and quality colleagues before it goes live, and that review is part of the schedule rather than an interruption to it. A capable agency writes to a claims matrix, references the specific evidence behind each claim, versions content so reviewers can see what changed, and builds review cycles into the timeline it quotes you. Ask a candidate how many review rounds they assume per asset and what happens to the deadline when a reviewer rejects a headline. Firms without medtech experience typically quote a generalist timeline and then miss it repeatedly, which is expensive in trust as well as in fees.
What moves the retainer
Content depth is the biggest driver, because credible medtech content is written by, or heavily reviewed by, people who understand the clinical and economic argument, and that expertise is not cheap. Audience count is second: marketing to clinicians, to hospital economic buyers and to patients means three content tracks rather than one. Regulatory review load is third and is routinely underestimated, since multiple review rounds on every asset consume real agency hours. Market count is fourth, because a device sold in several countries faces different regulatory regimes and different reimbursement stories. Congress and trade show support, product launch packages and video production are normally scoped as projects on top of the retainer. Ask for the split by workstream so proposals that bundle differently can be compared line by line.
How to vet a medtech agency
Ask for two or three live device or diagnostics properties they built and read them as a clinician would: are the claims specific and referenced, is the indication language precise, does the evidence page actually cite studies. Ask who on their team has sat through a regulatory review, and ask for that person on the call. Ask for a reference at a company at your stage, since marketing a first commercial device is a different job from supporting an established portfolio, and ask that reference specifically about how the agency handled a rejected claim. Then confirm the practical terms: who owns the content files and the claims matrix, how they handle confidentiality before a launch, and whether the work is bought as an ongoing retainer or as a launch project with a smaller retainer after it. Getting that structure right at the start is usually worth more than negotiating the rate.
Questions people ask about medtech marketing agency
Do I need an agency that specialises in medtech?
For anything making clinical claims, yes. The specialist premium buys familiarity with claims review, indication language and the evidence expectations of a value analysis committee. A generalist can be effective on brand, design or demand generation infrastructure, but pairing them with internal regulatory oversight has to be planned rather than assumed.
Can we market a device before it is cleared?
Promotion of an uncleared or unapproved device, or promotion beyond what the cleared indications support, is a regulatory matter and not a marketing judgement. Pre-clearance activity such as disease-state education and investor communication is handled carefully and under counsel. Ask your regulatory lead first, and expect a competent agency to insist on that.
How long is a realistic medtech content timeline?
Longer than a generalist agency will quote, because review rounds dominate. Ask candidates to build a schedule that names the number of review cycles per asset and the turnaround assumed for each, then compare timelines on that basis rather than on the headline delivery date.
What should we measure in a long sales cycle?
Leading indicators tied to the committee: qualified clinician enquiries, evidence downloads by target institutions, meetings booked at congresses, and how far named accounts have moved through the committee. Attributing revenue to a campaign across a multi-quarter cycle is unreliable, so agree the leading measures at the start.